Testicular Seminoma: Results of Treatment at the Northern Israel Oncology Center

Abstract

The survival, and the patterns and mechanisms of failure of 41 patients with pure testicular seminoma treated at the Northern Israel Oncology Center from 1968 to 1983 were analyzed. The actuarial 5-year survival of all patients was 85.4% and of stage I patients, 92.2%. Treatment failures were analyzed. The following conclusions were reached: in order to increase the cure rate, the use of combination chemotherapy as the initial treatment modality in advanced seminoma is recommended. In cases of transscrotal approach, the scrotum should be irradiated. Adjuvant mediastinal irradiation is not needed.

Cisplatin-based chemotherapy in advanced seminoma: Experience of the Northern Israel Oncology Center: 1981–1994

“…Four patients relapsed from complete remission following radiotherapy using previously described techniques [5]. The mean time to relapse was 7 months (range 4-12).…”